Lucid DiagnosticsLUCD 20 Cash Ratio is 0.95 as of Mar. 2026, which is 21% below its 10-year median of 1.21. GuruFocus rates LUCD with a GF Score™ of 20/100 and a GF Value™ of $0.82 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 843 Medical Devices & Instruments companies, Lucid Diagnostics ranks worse than 51.01% on this metric.
Lucid Diagnostics has a Cash Ratio of 0.95. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Lucid Diagnostics's Cash Ratio or its related term are showing as below:
LUCD'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 1.21 Max: 12.6
Current: 0.95
During the past 7 years, Lucid Diagnostics's highest Cash Ratio was 12.60. The lowest was 0.01. And the median was 1.21.
LUCD's Cash Ratio is ranked worse than 51.01% of 843
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs LUCD: 0.95
Lucid Diagnostics (NAS:LUCD) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Lucid Diagnostics Cash Ratio Related Terms
Lucid Diagnostics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lucid Diagnostics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (LUCD) has a Cash Ratio of 0.95 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lucid Diagnostics and its competitors. This is 21% below median its historical median of 1.21. Over the past decade, Lucid Diagnostics' Cash Ratio has ranged from 0.01 to 12.60. According to the industry distribution chart, Lucid Diagnostics ranks #430 out of 843 companies in the Medical Devices & Instruments industry, placing it in the top 51%.
Is Lucid Diagnostics' Cash Ratio too high?
Lucid Diagnostics' current Cash Ratio of 0.95 is 21% below median its 10-year median of 1.21. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 12.60. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Lucid Diagnostics' value of 0.95 is 2.1% below this industry median. Based on the distribution chart, Lucid Diagnostics ranks #430 out of 843 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Lucid Diagnostics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Cash Ratio compare to QTRX and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #430 out of 843 companies for Cash Ratio. This places Lucid Diagnostics in the lower half of its industry. The industry median Cash Ratio is 0.97. Lucid Diagnostics' value of 0.95 is 2.1% below this benchmark. Historically, Lucid Diagnostics' own Cash Ratio has ranged from 0.01 to 12.60 over the past decade. While the company's 10-year median is 1.21 vs. the industry median of 0.97, Lucid Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lucid Diagnostics's current Cash Ratio of 0.95 is 2.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lucid Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current Cash Ratio is 0.95, which is 21% below median its own 10-year median of 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.82, compared to a current price of $1.07 — trading 30.5% above its estimated fair value. The current Cash Ratio is 0.95, which is 21% below median its 10-year median of 1.21 and 2.1% below the Medical Devices & Instruments industry median of 0.97. Lucid Diagnostics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Cash Ratio is 0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $1.07 is trading 30.5% above its estimated GF Value™ of $0.82.
GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.
Key valuation signals for LUCD:
Cash Ratio: 0.95 (21% below median its 10-year median of 1.21)
GF Value™: $0.82 vs. price of $1.07 (30.5% above fair value)
Industry Position: 2.1% below the Medical Devices & Instruments median (#430 of 843)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
20GF Score
Get the complete analysis for LUCD
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
